Flubromazepam is a benzodiazepine derivative which was first synthesized in 1960,[1] but was never marketed and did not receive any further attention or study until late 2012 when it appeared on the grey market as a novel designer drug.[2][3][4][5][6][7][8]
Clinical data | |
---|---|
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 106 hours |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C15H10BrFN2O |
Molar mass | 333.160 g·mol−1 |
3D model (JSmol) |
|
| |
|
It is a structural analog of phenazepam in which the chlorine atom has been replaced by a fluorine atom.
An alternate isomer, 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-2H-1,4-benzodiazepin-2-one or "iso-flubromazepam",[9] may have been sold under the same name.[2]
In the UK, flubromazepam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.[10]
Flubromazepam, clonazolam, and flubromazolam are Schedule I controlled substances under Virginia State Law.[11]